Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revenio Group OyjREVXF 82 ROC (Joel Greenblatt) % is 72.87% as of Mar. 2026, which is 80% below its 10-year median of 365.79. GuruFocus rates REVXF with a GF Score™ of 82/100 and a GF Value™ of $41.11 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 98.57% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Revenio Group Oyj's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 72.87%.
The historical rank and industry rank for Revenio Group Oyj's ROC (Joel Greenblatt) % or its related term are showing as below:
REVXF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 148.42 Med: 365.79 Max: 666.04
Current: 148.42
During the past 13 years, Revenio Group Oyj's highest ROC (Joel Greenblatt) % was 666.04%. The lowest was 148.42%. And the median was 365.79%.
REVXF's ROC (Joel Greenblatt) % is ranked better than 98.57% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs REVXF: 148.42
Revenio Group Oyj's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -23.40% per year.
Revenio Group Oyj (OTCPK:REVXF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Revenio Group Oyj ROC (Joel Greenblatt) % Related Terms
Revenio Group Oyj ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REVXF vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Revenio Group Oyj's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's ROC (Joel Greenblatt) % falls into.
Revenio Group Oyj ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 72.87% mean?
Revenio Group Oyj (REVXF) has a ROC (Joel Greenblatt) % of 72.87% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Revenio Group Oyj and its competitors. This is 80% below median its historical median of 365.79. Over the past decade, Revenio Group Oyj's ROC (Joel Greenblatt) % has ranged from 148.42 to 666.04. According to the industry distribution chart, Revenio Group Oyj ranks #12 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 1.4%.
Is Revenio Group Oyj's ROC (Joel Greenblatt) % too high?
Revenio Group Oyj's current ROC (Joel Greenblatt) % of 72.87% is 80% below median its 10-year median of 365.79. Over the past 10 years, this metric has ranged from a low of 148.42 to a high of 666.04. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Revenio Group Oyj's value of 72.87% is 1658% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #12 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #12 out of 838 companies for ROC (Joel Greenblatt) %. This places Revenio Group Oyj in the top 1% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. Revenio Group Oyj's value of 72.87% is 1658% above this benchmark. Historically, Revenio Group Oyj's own ROC (Joel Greenblatt) % has ranged from 148.42 to 666.04 over the past decade. While the company's 10-year median is 365.79 vs. the industry median of 4.15, Revenio Group Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current ROC (Joel Greenblatt) % of 72.87% is 1658% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current ROC (Joel Greenblatt) % is 72.87%, which is 80% below median its own 10-year median of 365.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (REVXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.11, compared to a current price of $16.41 — trading 60.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 72.87%, which is 80% below median its 10-year median of 365.79 and 1658% above the Medical Devices & Instruments industry median of 4.15. Revenio Group Oyj's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current ROC (Joel Greenblatt) % is 72.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 60.1% below its estimated GF Value™ of $41.11.
GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.
Key valuation signals for REVXF:
ROC (Joel Greenblatt) %: 72.87% (80% below median its 10-year median of 365.79)
GF Value™: $41.11 vs. price of $16.41 (60.1% below fair value)
Industry Position: 1658% above the Medical Devices & Instruments median (#12 of 838)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
82GF Score
Get the complete analysis for REVXF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
